[{"indications": "Indications\u00a0essential hypertension", "name": "ALISKIREN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.5 Drugs affecting the renin-angiotensin system", "2.5.5.3 Renin inhibitors", "ALISKIREN"], "cautions": "Cautions\u00a0patients taking concomitant diuretics, on a low-sodium\r\ndiet, or who are dehydrated (first doses may cause hypotension\u2014initiate\r\nwith care); renal artery\r\nstenosis; patients at risk of renal impairment; monitor plasma-potassium concentration and renal function\r\nin diabetes mellitus and heart failure; history of angioedema (avoid in hereditary or idiopathic\r\nangioedema); interactions: Appendix 1 (aliskiren)", "side-effects": "Side-effects\u00a0diarrhoea; less commonly rash; rarely angioedema; peripheral oedema, acute renal failure\r\n(reversible on discontinuation of treatment), anaemia, and hyperkalaemia\r\nalso reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200250.htm", "doses": ["adult over 18 years, 150\u00a0mg\r\nonce daily, increased if necessary to 300\u00a0mg once daily "], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014no information available;\r\nother drugs acting on the renin-angiotensin system have been associated\r\nwith fetal malformations and neonatal death"}]